Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecanReport as inadecuate




Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan - Download this document for free, or read online. Document in PDF available to download.

Radiation Oncology

, 8:258

Clinical Radiation Oncology

Abstract

BackgroundTo compare the short-term tumor response and long-term clinical outcome of two preoperative chemoradiotherapy CRT regimens for locally advanced rectal cancer.

MethodsThis study included 231 patients scheduled for preoperative CRT using two chemotherapeutic protocols from April 2003–August 2006. Pelvic radiotherapy 50.4 Gy was delivered concurrently with capecitabine n = 148 or capecitabine-irinotecan n = 83. Surgery was performed 4–8 weeks after CRT completion. Tumor responses to CRT were assessed using both radiologic and pathologic measurements. Radiologic responses were evaluated by magnetic resonance volumetry, which was performed at the initial work-up and after completion of preoperative CRT just before surgery. Pathologic responses were assessed with downstaging ypStage 0-1 and grading tumor regression. Clinical outcomes were evaluated in terms of local control, relapse-free survival, and overall survival rates.

ResultsRadiologic examination demonstrated that tumor volume decreased by 65.6% in the capecitabine group and 66.8% capecitabine-irinotecan group p = 0.731. Postoperative pathologic stage determination showed that tumor downstaging occurred in 44.1% of the capecitabine group and 48.6% of the capecitabine-irinotecan group p = 0.538. The sum of tumor regression grade 3 near complete response and 4 complete response after CRT were 28.6% in the capecitabine group and 37.5% in the capecitabine-irinotecan group p = 0.247. There were no significant differences between the two groups in 5-year local control 91.7% vs. 92.5%; p = 0.875, relapse-free survival 80.8% vs. 77.2%; p = 0.685, and overall survival 88.4% vs. 90.4%; p = 0.723.

ConclusionsThis study revealed no differences in the short-term tumor response and long-term clinical outcome between preoperative capecitabine and capecitabine-irinotecan CRT regimens for locally advanced rectal cancer.

KeywordsRectal cancer Preoperative chemoradiotherapy Capecitabine Irinotecan Electronic supplementary materialThe online version of this article doi:10.1186-1748-717X-8-258 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Sung Uk Lee - Dae Yong Kim - Sun Young Kim - Ji Yeon Baek - Hee Jin Chang - Min Ju Kim - Tae Hyun Kim - Ji Won Par

Source: https://link.springer.com/







Related documents